北京大学学报(医学版) ›› 2021, Vol. 53 ›› Issue (4): 793-797. doi: 10.19723/j.issn.1671-167X.2021.04.029

• 技术方法 • 上一篇    下一篇

嗜铬细胞瘤和副神经节瘤二次手术策略

刘磊,秦艳春,王国良,张树栋,侯小飞,马潞林()   

  1. 北京大学第三医院泌尿外科, 北京 100191
  • 收稿日期:2021-03-22 出版日期:2021-08-18 发布日期:2021-08-25
  • 通讯作者: 马潞林 E-mail:malulin@medmail.com.cn

Strategy of reoperation for pheochromocytoma and paraganglioma

LIU Lei,QIN Yan-chun,WANG Guo-liang,ZHANG Shu-dong,HOU Xiao-fei,MA Lu-lin()   

  1. Department of Urology, Peking University Third Hospital, Beijing 100191, China
  • Received:2021-03-22 Online:2021-08-18 Published:2021-08-25
  • Contact: Lu-lin MA E-mail:malulin@medmail.com.cn

RICH HTML

  

摘要:

目的: 分析嗜铬细胞瘤和副神经节瘤二次手术的策略和总结经验教训。方法: 回顾性分析2016年8月至2021年2月北京大学第三医院泌尿外科7例嗜铬细胞瘤和副神经节瘤实施二次手术的临床资料,其中男性 4 例、女性 3 例,平均(44.1±11.5)岁(28~60岁),右侧6例,左侧1例。二次手术的原因包括:(1)肿瘤切除后复发的病例2例;(2)肿瘤体积大并与血管关系密切,首次手术未能成功切除肿瘤的病例3例;(3)术前未诊断出嗜铬细胞瘤和副神经节瘤而没有进行药物准备,首次手术中出现血压剧烈波动而中止手术的病例2例。所有病例都进行了影像学评估、儿茶酚胺检查和充分肾上腺素能α受体阻滞剂的药物准备。手术方式包括经腹开放手术4例、机器人辅助腹腔镜手术1例、后腹腔镜手术2例。应用的创新技术包括翻肝技术、下腔静脉切断再吻合技术、左肾静脉切断技术。结果: 肿瘤平均大小 (8.0±3.2) cm (3.6~13.9 cm)。二次手术距首次手术的中位时间9个月(四分位数间距:6, 19个月)。二次手术中位手术时间407 min(四分位数间距:114, 430 min),中位出血量1 500 mL(四分位数间距:20, 3 800 mL)。5例手术成功,1例术中仅做探查未能成功切除肿瘤,围手术期死亡1例。术中输血5例,中位输注悬浮红细胞800 mL(四分位数间距:0, 2 000 mL),术后淋巴漏1例,保守治疗自愈。切断左肾静脉及下腔静脉切除再吻合病例,术后肾功能正常。术后平均住院天数(7.2±3.3) d (4~13 d)。存活6例患者中位随访33.5个月(四分位数间距:4.8, 48.0个月),手术未成功病例仍带瘤生存,余病例尚无复发。结论: 首次开放手术不能成功切除和复发的嗜铬细胞瘤和副神经节瘤二次手术难度大,出血多,手术风险高,存在手术失败和围手术期死亡风险,需要根据具体的情况采用不同的手术方式和策略。

关键词: 嗜铬细胞瘤, 副神经节瘤, 二次手术, 复发

Abstract:

Objective: To explore the surgical strategy and experience of reoperation for pheochromocytoma and paraganglioma which is very challenging. Methods: The clinical data of 7 patients with pheochromocytoma and paraganglioma who underwent reoperation in Department of Urology, Peking University Third Hospital from August 2016 to February 2021 were analyzed retrospectively. There were 4 males and 3 females, with an average age of (44.1±11.5) years (28-60 years), 6 cases on the right side and 1 case on the left side. The causes of the operations included: (1) 2 cases of tumor recurrence after resection; (2) The primary operations failed to completely remove the tumors in 3 cases, because the tumors were large and closely related to blood vessels. (3) Pheochromocytoma and paraganglioma wasn’t diagnosed before primary operation, therefore, drug preparation wasn’t prepared. Two cases were interrupted by severe blood pressure fluctuations during the primary operations. Imaging evaluation, catecholamine biochemical examination and adequate adrenergic α receptor blockers were administrated in all the cases. The surgical approaches included open transperitoneal surgery in 4 cases, robot-assisted laparoscopy in 1 case and retroperitoneal laparoscopy in 2 cases. The innovative techniques included mobilization of the liver, inferior vena cava transection and anastomosis, and transection of left renal vein. Results: The average tumor size was (8.0±3.2) cm (3.6-13.9 cm). The median interval between the reoperation and the primary operation was 9 months (IQR: 6,19 months). The median operation time was 407 min (IQR: 114, 430 min) and the median blood loss was 1 500 mL (IQR: 20, 3 800 mL). Operations of 5 cases were performed successfully, and 1 case failed only by exploration during the operation. One case died perioperatively. There were 5 cases of intraoperative blood transfusion, the median transfusion volume of red blood cells was 800 mL (IQR: 0, 2 000 mL). One case experienced postoperative lymphorrhagia, and recovered after conservative treatment. The renal function was normal in 2 cases after resection and anastomosis of inferior vena cava or transection of left renal vein. The average postoperative hospital stay was (7.2±3.3) d (4-13 d). The median follow-up time of 6 patients was 33.5 months (IQR: 4.8, 48.0 months). The case who failed in the reoperation still survived with tumor and there was no recurrence in the rest of the patients. Conclusion: The reoperation of pheochromocytoma and paraganglioma, which can not be resected in the primary operation or recurred postoperatively, is difficult with high risk of hemorrhage, and there is a risk of failure and perioperative death. Different surgical approaches and strategies need to be adopted based on the different situation.

Key words: Pheochromocytoma, Paraganglioma, Reoperation, Recurrence

中图分类号: 

  • R737.1

图1

嗜铬细胞瘤和副神经节瘤病例二次手术前影像学表现"

表1

病例的临床资料及围手术期数据"

Items Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7
Gender Female Female Male Male Male Male Female
Age/years 36 28 49 33 45 58 60
Side Right Right Right Right Right Right Left
Interval to primary surgery/months 108 9 6 6 18 1 19
BMI/ (kg/m2) 20.9 25.8 26.0 21.5 27.2 27.3 32.8
ASA 2 2 2 2 3 2 2
Size/cm 8.7 13.9 9.2 7.4 7.4 3.6 5.9
Location Retrohepatic Retrocaval Retrocaval Retrocaval Retrocaval Normal Para-aortic
Preoperative albumin/ (g/L) 45.6 42.2 46.7 48.6 48.8 43.3 45.8
Preoperative total protein/ (g/L) 69.0 65.6 76.3 74.5 77.7 69.0 75.3
Preoperative hemoglobin/ (g/L) 141.0 87.0 136.0 144.0 154.0 136.0 135.0
Postoperative hemoglobin/ (g/L) 125.0 123.0 103.0 115.0 128.0 120.0
Operation time /min 421 430 407 520 283 111 114
Blood loss/mL 1 500 12 000 1 600 1 500 3 800 20 20
Complication Dead Failed to
resect tumor
Lymphorrhagia
Approach Open Open Open Open Robotic Laparoscopic Laparoscopic
Blood transfusion volume/mL 800 5000 1600 800 2000 0 0
Innovative technique Mobilization
of the liver
Resection and
anastomosis of IVC
Transection of
left renal vein
Postoperative hospital stay/d 6 6 9 13 5 4
Followup /months 46 39 28 1 54 6
Outcome No recurrence Dead No recurrence No recurrence No recurrence No recurrence No recurrence
[1] Hamidi O, Young WF Jr., Iñiguez-Ariza NM, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years [J]. J Clin Endocrinol Metab, 2017, 102(9):3296-3305.
doi: 10.1210/jc.2017-00992
[2] Davison AS, Jones DM, Ruthven S, et al. Clinical evaluation and treatment of phaeochromocytoma [J]. Ann Clin Biochem, 2018, 55(1):34-48.
doi: 10.1177/0004563217739931 pmid: 29027806
[3] Hamidi O, Young WF Jr., Gruber L, et al. Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A syste-matic review and meta-analysis [J]. Clin Endocrinol (Oxf), 2017, 87(5):440-450.
doi: 10.1111/cen.2017.87.issue-5
[4] Lam AK. Update on adrenal tumours in 2017 World Health Orga-nization (WHO) of endocrine tumours [J]. Endocr Pathol, 2017, 28(3):213-227.
doi: 10.1007/s12022-017-9484-5
[5] Wilhelm SM, Prinz RA, Barbu AM, et al. Analysis of large versus small pheochromocytomas: Operative approaches and patient outcomes [J]. Surgery, 2006, 140(4):553-560.
doi: 10.1016/j.surg.2006.07.008
[6] Amar L, Servais A, Gimenez-Roqueplo AP, et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma [J]. J Clin Endocrinol Metab, 2005, 90(4):2110-2116.
doi: 10.1210/jc.2004-1398
[7] Edstrom Elder E, Hjelm Skog AL, Hoog A, et al. The management of benign and malignant pheochromocytoma and abdominal paraganglioma [J]. Eur J Surg Oncol, 2003, 29(3):278-283.
doi: 10.1053/ejso.2002.1413
[8] Sbardella E, Grossman AB. Pheochromocytoma: An approach to diagnosis [J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(2):101346.
doi: S1521-690X(19)30097-1 pmid: 31708376
[9] Sonbare DJ, Abraham DT, Rajaratnam S, et al. Re-operative surgery for pheochromocytoma-paraganglioma: Analysis of 13 cases from a single institution [J]. Indian J Surg, 2018, 80(2):123-127.
doi: 10.1007/s12262-017-1658-3 pmid: 29915477
[10] Aggeli C, Nixon AM, Parianos C, et al. Surgery for pheochromocytoma: A 20-year experience of a single institution [J]. Hormones (Athens), 2017, 16(4):388-395.
[11] Hassan T, de la Taille A, Ingels A. Right robot-assisted partial adrenalectomy for pheochromocytoma with video [J]. J Visc Surg, 2020, 157(3):259-260.
doi: S1878-7886(20)30057-6 pmid: 32198067
[12] Soejima Y, Yoshizumi T, Ikegami T, et al. Surgical resection of giant pheochromocytomas arising behind the retrohepatic inferior vena cava [J]. Anticancer Res, 2017, 37(1):277-280.
pmid: 28011503
[1] 李雨清,王飚,乔鹏,王玮,关星. 经耻骨后尿道中段悬吊带术治疗女性复发性压力性尿失禁的中长期疗效[J]. 北京大学学报(医学版), 2024, 56(4): 600-604.
[2] 姚中强,李常虹,李欣艺,郭苇,翟佳羽,刘蕊,魏慧,穆荣. 抗磷脂酰丝氨酸/凝血酶原抗体与不明原因复发性流产的相关性分析[J]. 北京大学学报(医学版), 2023, 55(6): 1058-1061.
[3] 陈素华,杨军,陈新,杨辰龙,孙建军,林国中,于涛,杨欣,韩芸峰,吴超,司雨,马凯明. 大型、巨大型上矢状窦中后1/3侵犯颅外复发脑膜瘤的手术治疗[J]. 北京大学学报(医学版), 2022, 54(5): 1006-1012.
[4] 王跃,张爽,张虹,梁丽,徐玲,程元甲,段学宁,刘荫华,李挺. 激素受体阳性/人表皮生长因子受体2阴性乳腺癌临床病理特征及预后[J]. 北京大学学报(医学版), 2022, 54(5): 853-862.
[5] 森本智惠子,王益勤,周蓉,王建六. 子宫内膜非典型增生及子宫内膜癌患者保留生育功能治疗的临床研究[J]. 北京大学学报(医学版), 2022, 54(5): 936-942.
[6] 于焕斌,伍文杰,吕晓鸣,石妍,郑磊,张建国. 125I粒子近距离治疗外放疗后复发唾液腺癌[J]. 北京大学学报(医学版), 2020, 52(5): 919-923.
[7] 刘鹭,田杰,吴恺,高莹,张争,张俊清,郭晓蕙. 血浆游离型甲氧基肾上腺素类物质检测正常的嗜铬细胞瘤和副神经节瘤的临床特点[J]. 北京大学学报(医学版), 2020, 52(4): 614-620.
[8] 熊盛炜,王杰,朱伟杰,程嗣达,张雷,李学松,周利群. 二次肾盂成形术在复发性肾盂输尿管连接部梗阻中的研究进展[J]. 北京大学学报(医学版), 2020, 52(4): 794-798.
[9] 侯磊,叶国华,刘筱菁,李自力. 下颌后缩伴颞下颌关节重度骨关节病患者正颌术后颌骨稳定性及髁突体积变化的评价[J]. 北京大学学报(医学版), 2020, 52(1): 113-118.
[10] 张旭初,张建华,王荣福,范岩,付占立,闫平,赵光宇,白艳霞. 18F-FDG PET/CT联合多种肿瘤标志物在结直肠中分化腺癌术后复发及转移中的应用价值[J]. 北京大学学报(医学版), 2019, 51(6): 1071-1077.
[11] 唐琦,林榕城,姚林,张争,郝瀚,张崔建,蔡林,李学松,何志嵩,周利群. 肾癌术后局部复发患者的临床病理特征及预后分析[J]. 北京大学学报(医学版), 2019, 51(4): 628-631.
[12] 朱冉,倪照军,张顺,庞良俊,王传升,鲍彦平,孙洪强. 临床特征对酒精依赖复发的影响:前瞻性队列研究[J]. 北京大学学报(医学版), 2019, 51(3): 519-524.
[13] 李欣艺,赵金霞,刘湘源. 抗磷脂抗体相关性复发性流产的诊治:附75例抗磷脂综合征患者妊娠期用药和结局分析[J]. 北京大学学报(医学版), 2018, 50(6): 956-961.
[14] 吴恺,张杨,张红,檀增桓,郭晓蕙,杨建梅. 嗜铬细胞瘤/副神经节瘤患者RET、VHL、SDHD、SDHB遗传基因变异的检测[J]. 北京大学学报(医学版), 2018, 50(4): 634-639.
[15] 邢云超,熊耕砚,方东,张争,蔡林,张雷,何志嵩,李学松,周利群. 上尿路尿路上皮癌术前预后相关因素分析及初步风险分层模型构建[J]. 北京大学学报(医学版), 2016, 48(6): 1032-1037.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!